Figure 3

a

<table>
<thead>
<tr>
<th></th>
<th>Serum</th>
<th>IgG-depleted serum</th>
<th>IgG</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG (g/l)</td>
<td>8.2 ± 1</td>
<td>&lt;0.008*</td>
<td>2 ± 0.3</td>
</tr>
<tr>
<td>IgA (g/l)</td>
<td>6.3 ± 2.2</td>
<td>1.9 ± 0.7</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>PR3-ANCA IgG (IU/ml)</td>
<td>33 ± 8.5</td>
<td>&lt;0.2*</td>
<td>58.8 ± 25.4</td>
</tr>
<tr>
<td>MPO-ANCA IgG (IU/ml)</td>
<td>40 ± 19.6</td>
<td>&lt;0.2*</td>
<td>81.1 ± 26</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SEM; *Below the detection limit of ELISA
Figure 4

(a) 

(b) 

Fold induction

- TNFα
+ TNFα

IgG 25ug/ml
IgG 250ug/ml
Serum
IgG-depleted serum

Legend:
- TNF-α stimulated
- Unstimulated
- Isotype control
Figure 5

a

C5aR antagonist

b

Eculizumab

Fold Induction

C5aR antagonist

Eculizumab (μg/ml)